Know Cancer

or
forgot password

Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma


N/A
N/A
50 Years
Not Enrolling
Both
Lymphoma, Non-Hodgkin, Leukemia, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin

Thank you

Trial Information

Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma


To determine the disease free survival and overall survival of patients with ALL and ANLL
after induction failure, in relapse, or subsequent remission from CML in several phases or
recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and
cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling
donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide
(CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia
or High Grade Lymphoma


Inclusion Criteria:

HLA identical donor

- adequate organ function

- other life threatening disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

overall survival

Outcome Time Frame:

october 2009

Safety Issue:

No

Principal Investigator

Robert Lowsky

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

BMT34

NCT ID:

NCT00186290

Start Date:

December 1989

Completion Date:

October 2009

Related Keywords:

  • Lymphoma, Non-Hodgkin
  • Leukemia
  • Blood and Marrow Transplant (BMT)
  • Lymphomas: Non-Hodgkin
  • Leukemia
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location

Stanford University School of MedicineStanford, California  94305-5317